Lars Vibe Andreasen

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

Jaap T. van Dissel, Simone A. Joosten, Søren T. Hoff et al. · Vaccine · 2014 · 243 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01

Anders Fomsgaard, Ingrid Karlsson, Gregers J. Gram et al. · Vaccine · 2011 · 69 citations

Life Sciences, Immunology, Infectious Diseases +17

Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau

Raúl Gómez Román, Kristoffer Jarlov Jensen, Sanne Jensen et al. · AIDS Research and Human Retroviruses · 2013 · 55 citations

Veterinary Medicine, Immunology, Infectious Diseases +17

Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma

Sofie Kirial Mørk, Mohammad Kadivar, Kalijn F. Bol et al. · Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) · 2022 · 45 citations · Full text

Life Sciences, Immunology, Oncology +17

Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection

Ingrid Karlsson, Lea Brandt, Lasse Vinner et al. · Clinical Immunology · 2012 · 44 citations

Life Sciences, Immunology, Infectious Diseases +16